Circulating Biomarkers and AI in Therapeutics and Clinical Risk Management: From Molecular Signals to Precision Medicine
Deadline 2026-12-31Taylor & FrancisIndexed (Active)
Journal: Therapeutics and Clinical Risk Management
Circulating biomarkers are increasingly reshaping the landscape of modern medicine by enabling minimally invasive, dynamic assessment of disease processes across diverse clinical settings. Among these, cell-free DNA (cfDNA) has emerged as a particularly versatile analyte, offering insights into tissue damage, clonal evolution, and therapeutic response in real time. Beyond its established role in oncology, cfDNA and…
Current and Emerging Strategies in the Management of Cardiac Arrhythmias
Deadline 2026-12-31Taylor & FrancisIndexed (Active)
Journal: Therapeutics and Clinical Risk Management
Cardiac arrhythmias remain a major cause of morbidity, mortality, hospitalization, and impaired quality of life worldwide. They encompass a broad and increasingly complex spectrum of disorders, ranging from atrial fibrillation and supraventricular tachycardias to ventricular arrhythmias, conduction disease, and inherited arrhythmic syndromes. Over the past few years, the field has evolved rapidly, driven by major ad…
Novel Biomarkers and Molecular Biology of Solid Tumors
Deadline 2027-01-31Taylor & FrancisIndexed (Active)
Journal: Therapeutics and Clinical Risk Management
Solid tumors are biologically heterogeneous diseases shaped by dynamic interactions among genomic alterations, epigenetic states, transcriptional programs, the tumor microenvironment, and host factors. As a result, there is growing interest in biomarkers that can capture tumor behavior more accurately than conventional clinicopathologic variables alone. This Article Collection will focus on emerging biomarkers and m…
Neurological Adverse Drug Reactions and Clinical Risk
Deadline 2027-03-31Taylor & FrancisIndexed (Active)
Journal: Therapeutics and Clinical Risk Management
Neurological adverse drug reactions (ADRs) represent a broad group of drug-related effects involving the central and peripheral nervous systems. These reactions range from symptoms such as headache, dizziness, and somnolence to more severe manifestations, including cognitive impairment, seizures, and peripheral neuropathy. As pharmacotherapy continues to expand across multiple therapeutic areas, the burden of neurol…
Immunotherapy and Risk Management in Hepatobiliary and Pancreatic Malignancies
Deadline 2027-04-30Taylor & FrancisIndexed (Active)
Journal: Therapeutics and Clinical Risk Management
In recent years, immunotherapy-particularly immune checkpoint inhibitors-has dramatically changed the therapeutic landscape of hepatobiliary and pancreatic (HBP) malignancies, including hepatocellular carcinoma, biliary tract cancers, and pancreatic cancer. Combination strategies involving immunotherapy with chemotherapy, radiotherapy, and locoregional treatments are increasingly adopted in clinical practice. Howeve…
Reference integrity note: verify every citation against the original source before submission, including publication year, journal title, volume/issue, page range, DOI, and the target journal style.
DrAIStudio